Investigators note a supply shortage led to use of half a dose for imaging purposes.

In this EyePod® episode, David Hutton sits down with Shankar Musunuri, CEO of Ocugen to discuss updated data for OCU400.

The organization is warning the public about the hazards of misusing contact lenses. Contact lens wearers also must take extra care when applying and removing eye cosmetics.

The effort will capture the real-life stories of patients and eye care professionals around the world.

According to the company, the divestment includes Xiidra, on-market treatment for dry eye disease and additional ophthalmic investigational therapies. Novartis will now move forward with a focused portfolio and prioritized therapeutic areas for future growth.

A team of University of Rochester scientists develop computer models of patients’ eyes to identify the ideal IOLs and visual simulators for patients to experience how they will see with them.

According to Outlook, in the FDA’s recently issued CRL it concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.

The specialty pharmaceutical research company’s new retinal vascular dysfunction model can have an impact on the research and development of new drugs for retinal vascular diseases.

In cases where patients struggle with applying or tolerating eye drops, especially after previous selective laser trabeculoplasty (SLT) treatment, MicroPulse transscleral laser therapy (TLT) offers a practical solution.

Glaucoma specialist Joel Solano, MD, connects patients diagnosed with glaucoma with digital health solutions that can help prevent blindness and vision loss.

Kriya is developing a one-time gene therapy designed to block complement C3 and C5, which are clinically validated substrates targeted by FDA approved therapies, to delay the progression of geographic atrophy.

Efficacy of treatment option is also confirmed in pediatric population in India.

The Lasker-DeBakey Clinical Medical Research Award, dubbed ‘America’s Nobel,’ recognizes the wide use of optical coherence tomography to manage eye disease, prevent blindness.

The company announced its previously announced agreement to divest its late-stage ophthalmic assets to Laboratoires Théa S.A.S. has been terminated.

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents.